WVP
PTCT icon

Worth Venture Partners’s PTC Therapeutics PTCT Stock Holding History

Worth Venture Partners’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-12,800
Closed -$63.4K – 195
2023
Q1 		$63.4K Buy
+12,800
New +$585K 0.03% 150
2017
Q4 		– Sell
-187,600
Closed -$412K – 137
2017
Q3 		$412K Buy
+187,600
New +$3.67M 0.36% 55

Other funds holding PTCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Worth Venture Partners's PTCT Position: Q2 2023 in Review

Worth Venture Partners sold out of PTC Therapeutics (PTCT) in Q2 2023, closing a stake of 8,956 shares — an estimated $434K sold.

Worth Venture Partners first reported a position in PTCT in Q3 2017 and held it in 2 quarters. The position peaked at $1.32M in Q3 2017. 204 funds tracked by Wall St. Rank hold PTCT as of Q2 2023.

  • Worth Venture Partners reported no remaining PTC Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Worth Venture Partners sold 8,956 PTC Therapeutics shares in Q2 2023, an estimated $434K.
  • Worth Venture Partners first reported a position in PTC Therapeutics in Q3 2017 and held it in 2 quarters.
  • Worth Venture Partners's PTC Therapeutics position peaked at $1.32M in Q3 2017.
  • 204 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.